À retenir
Among 32,451 UK Biobank participants, those in the highest arterial stiffness tertile had higher risks of probable sarcopenia (HR 1.38, 95% CI 1.22-1.55) and sarcopenia (HR 1.56, 95% CI 1.11-2.18) than the lowest tertile. This is observational, so it shows association; the mediation by biological aging is a model-based estimate.
Study design
Étude de cohorte
Reading basis
Published abstract
Reading focus
Association & confounding
Cette explication éditoriale existe en anglais, chinois simplifié et chinois traditionnel. Cette interface affiche la lecture en anglais.
Question de recherche
Stiffer arteries may contribute to sarcopenia (loss of muscle mass and strength), but it is unclear whether faster biological aging explains the link or whether frailty changes it. The authors tested these ideas in a large cohort.
Population et méthode
Prospective cohort of 32,451 UK Biobank participants free of probable sarcopenia and sarcopenia at baseline. Cause-specific Cox proportional hazards models related arterial stiffness index (ASI) to incident probable sarcopenia and sarcopenia, with restricted cubic splines for dose-response. Counterfactual mediation analysis tested Klemera-Doubal biological age acceleration (KDM-BAacc), and multiplicative and additive interaction analyses tested effect modification by frailty. Sensitivity analyses were also run. The abstract does not give follow-up length or adjustment variables.
Résultats
The authors’ reported results. Read each estimate with its population and uncertainty.
- 1During follow-up, 1,901 participants developed probable sarcopenia and 277 developed sarcopenia.
- 2Highest versus lowest ASI tertile: HR 1.38 (95% CI 1.22-1.55) for probable sarcopenia and HR 1.56 (95% CI 1.11-2.18) for sarcopenia.
- 3ASI had a nonlinear association with probable sarcopenia and a linear association with sarcopenia.
- 4KDM-BAacc significantly mediated 8.66% and 18.85% of the associations with probable sarcopenia and sarcopenia. Frailty modified the associations, which were largely confined to non-frail participants.
Limites et incertitude
- 1Observational data cannot prove that arterial stiffness causes sarcopenia; unmeasured factors could drive both.
- 2Only 277 people developed sarcopenia, so the estimate for it is less precise (CI 1.11-2.18) than for probable sarcopenia.
- 3Mediation by biological aging relies on assumptions of the model, and the result that the link is mostly in non-frail people is unexpected and needs replication.
- 4This reading is based on the abstract only.
Mise en perspective
Higher arterial stiffness goes with a higher chance of developing low muscle strength or mass later, especially in people who are not yet frail. This does not show that lowering stiffness prevents sarcopenia. Questions about arterial stiffness or muscle loss belong with your clinician.
Vos données
Arterial stiffness index in the study came from a clinical device; some wearables estimate pulse-wave measures, but these are not the same measurement. Grip strength and blood pressure trends are more practical to follow; use the same device and conditions each time.
Comprendre ce type de preuve
Exposure precedes follow-up outcomes, but confounding and reverse causation can remain. A hazard ratio is not an individual absolute risk or a demonstrated intervention effect.
Résumé structuré des auteurs English
Le résumé original en anglais est reproduit avec attribution sous la licence ouverte indiquée. Il s’agit d’une source, pas d’une interprétation MoveVitals. L’analyse préparée figure ci-dessus ; vérifiez les conclusions importantes dans la source.
Background
Arterial stiffness may contribute to sarcopenia, but whether biological aging mediates and frailty modifies these associations remains unclear.
Methods
This prospective cohort study included 32,451 UK Biobank participants free of probable sarcopenia and sarcopenia at baseline. Cause-specific Cox proportional hazards models were used to examine the associations between arterial stiffness index (ASI) and incident probable sarcopenia and sarcopenia. Restricted cubic spline analyses were performed to characterize dose-response relationships. Counterfactual mediation analysis was used to evaluate the mediating role of Klemera-Doubal biological age acceleration (KDM-BAacc), while multiplicative and additive interaction analyses were conducted to assess effect modification by frailty. Sensitivity analyses were performed to evaluate the robustness of the findings.
Results
During follow-up, 1,901 participants developed probable sarcopenia and 277 developed sarcopenia. Compared with the lowest ASI tertile, participants in the highest tertile had higher risks of probable sarcopenia (HR 1.38, 95% CI 1.22-1.55) and sarcopenia (HR 1.56, 95% CI 1.11-2.18). ASI showed a nonlinear association with probable sarcopenia but a linear association with sarcopenia. KDM-BAacc significantly mediated 8.66 and 18.85% of the associations with probable sarcopenia and sarcopenia, respectively. Frailty significantly modified these associations, with the associations largely confined to non-frail participants. These findings were robust in sensitivity analyses.
Conclusion
Higher ASI was associated with increased risks of incident probable sarcopenia and sarcopenia. Biological aging partially mediated these associations, whereas frailty modified their magnitude. These findings identify arterial stiffness as a potential upstream determinant of sarcopenia, with biological aging as a mediating pathway and frailty as a modifier of susceptibility.
Sources et attribution
Biological aging mediates and frailty modifies the associations of arterial stiffness with incident probable sarcopenia and sarcopenia: a prospective cohort study of UK biobank.
Sun A, Du Y, Yang X, Liu H, Zeng R, Wu Y, Liu Z.
Frontiers in public health · 2026-09-14
DOI: 10.3389/fpubh.2026.1926399 ↗PubMed · 42807006 ↗Europe PMC · Licence indiquée: cc by ↗Abstract © the original authors, reproduced under the recorded open licence. Translations support reading; use the English record to check terminology and numerical results. Our methodological interpretation is separate from the authors’ conclusions.
Interprétation éditoriale MoveVitals · contenu éducatif · aucune évaluation clinique individuelle enregistrée
Sources vérifiées 2026-11-01
Guides pratiques
À lire ensemble
ACSM review of 137 reviews: resistance training works, and few programme details matter
The American College of Sports Medicine pooled 137 systematic reviews (over 30,000 healthy adults) and concluded that resistance training beats no exercise for strength, muscle size, power, endurance and several function tests. Few programme details changed results consistently: heavier loads (80% or more of one-repetition maximum) and 2 to 3 sets favoured strength, and at least 10 sets a week favoured muscle size, while training to failure, exercise type and periodization did not. It summarises reviews rather than new trials, gives no pooled effect sizes, and drew mostly on untrained adults and overlapping source trials.
Medicine & Science in Sports & Exercise
Nearly every resistance training plan beat no exercise; heavy loads led for strength
In a network meta-analysis of randomised trials in healthy adults (178 studies and 5097 people for strength, 119 studies and 3364 people for muscle size), nearly all resistance training prescriptions beat no exercise. Higher-load, multiset, thrice-weekly training ranked best for strength (standardised mean difference 1.60, 95% credible interval 1.38 to 1.82) and higher-load, multiset, twice-weekly training for muscle size (0.66, 0.47 to 0.85). Most prescriptions could not be statistically separated from each other (the 95% interval contained zero in 91% of the comparisons between them) and risk of bias was moderate to high, so the rankings are tentative.
British Journal of Sports Medicine
Muscle-strengthening linked to lower risk of death, heart disease, cancer and diabetes
Pooling 16 prospective cohort studies of adults, people who did muscle-strengthening activity had a 15% lower risk of all-cause mortality (RR 0.85, 95% CI 0.79 to 0.93) and a 17% lower risk of both cardiovascular disease and diabetes (RR 0.83 for each) than people who did none. The pooled mortality curve was lowest at about 40 min/week (RR 0.83), but whether larger amounts help or hurt is unclear. All of this is observational, from mostly US self-reported data, and the authors rated the certainty of evidence as very low for most outcomes.
British Journal of Sports Medicine
Protein supplements and weight training: small extra gains, smaller in older adults
Pooling 49 randomised trials with 1,863 healthy adults who did resistance training for at least 6 weeks, protein supplements added 0.30 kg of fat-free mass (95% CI 0.09 to 0.52) and 2.49 kg of one-repetition-maximum strength (0.64 to 4.33) on top of training alone. These gains were small next to the effect of training itself, were weaker with older age, and the suggested plateau near 1.6 g/kg/day was not statistically significant (p=0.079). One author has received funding from the US National Dairy Council, which supported trials in the analysis.
British Journal of Sports Medicine

